Hegseth's plan to screen military members for low testosterone raises concern for doctors: "Not a performance drug"

Key Points:

• Defense Secretary Pete Hegseth announced annual testosterone deficiency screenings for U.S. service members over 30, with optional testing for younger personnel, aiming to optimize performance through potential testosterone replacement therapy.
• Medical experts and organizations like The Endocrine Society caution against widespread testosterone screening, citing natural fluctuations in hormone levels and lack of evidence that treatment improves strength or combat readiness.
• Testosterone replacement therapy carries risks including blood clots, fertility issues, and overtreatment due to false positives, with experts emphasizing that low testosterone symptoms often stem from other causes like stress or poor sleep.
• The policy's implementation could be costly, with estimated expenses in the tens of millions annually for testing and follow-up, raising concerns about the efficient use of military healthcare resources.
• The announcement aligns with broader trends in wellness and body optimization, though medical professionals warn that increasing testosterone beyond normal levels does not necessarily enhance health or performance.